Neuroprotective compounds from endophytic fungi metabolites of Rhodiola tibetica attenuate post-stroke deficits via multi-targeted modulation of neuroinflammation.

Researchers studied three natural compounds extracted from fungi living inside Rhodiola tibetica, a medicinal plant used in traditional medicine, to see if they could help recovery after stroke. Stroke is a leading cause of disability, and current treatments work best when given immediately—there are few options for people seeking help days after a stroke occurs.

In this study, scientists gave mice one of three compounds (called JK-1, TXY-1, and R11-6) starting three days after an induced stroke. After just one to two weeks of treatment, the mice showed significant improvements in movement and coordination compared to untreated mice. The compounds appeared to work by reducing brain inflammation and protecting nerve cells in the damaged areas. Specifically, they calmed overactive immune cells in the brain, reduced inflammatory molecules, and boosted the body's natural protective responses.

While this study focused on herbal compounds rather than acupuncture, it's relevant to acupuncture patients because both approaches share similar goals: reducing inflammation and supporting the body's natural healing processes after neurological injury. Traditional Chinese Medicine has long used Rhodiola species for various conditions, and acupuncture is increasingly studied for stroke rehabilitation. The anti-inflammatory mechanisms identified in this research may overlap with how acupuncture helps stroke recovery, though more research is needed to understand these connections.

This laboratory study shows promise but has only been tested in animals so far. If you're considering complementary approaches like acupuncture for stroke recovery, work with a licensed acupuncturist experienced in neurological rehabilitation.

This preclinical study evaluated three compounds (JK-1, TXY-1, R11-6) derived from endophytic fungi of Rhodiola tibetica for post-stroke neuroprotection. Using a photothrombotic stroke model in mice, researchers administered compounds orally beginning 3 days post-stroke—a clinically relevant delayed intervention timeframe. After 1-2 weeks of treatment, all three compounds significantly improved neurological function, reduced foot-fault rates, and shortened adhesive-removal latencies compared to controls.

Histological analysis revealed increased neuronal density and preservation of synaptic proteins (PSD-95, p-CaMKII) in peri-infarct cortex. Mechanistically, compounds suppressed the pro-inflammatory NF-κB/NLRP3 axis, attenuated microglial M1 polarization and astrocytic reactivity, while upregulating endogenous protective factors IL-10 and HO-1. TXY-1 and R11-6 demonstrated superior HO-1 induction correlating with greater NF-κB suppression.

Clinical relevance: These findings support multi-targeted anti-inflammatory approaches in post-acute stroke management. The delayed administration protocol and oral bioavailability suggest translational potential. For practitioners incorporating herbal medicine, Rhodiola-derived compounds may complement conventional stroke rehabilitation, though human trials are needed.